Detalhe da pesquisa
1.
A randomized, open-label, 5-period crossover study evaluating the pharmacokinetics and safety of a single dose of intranasal dihydroergotamine (DHE) powder (STS101), intramuscular DHE mesylate, and liquid nasal spray DHE in healthy adults.
Headache
; 64(3): 266-275, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-38413540
2.
A Phase 1, Randomized, Open-Label, Safety, Tolerability, and Comparative Bioavailability Study of Intranasal Dihydroergotamine Powder (STS101), Intramuscular Dihydroergotamine Mesylate, and Intranasal DHE Mesylate Spray in Healthy Adult Subjects.
Headache
; 60(4): 701-712, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-31985049
3.
Dihydroergotamine and triptan use to treat migraine during pregnancy and the risk of adverse pregnancy outcomes.
Sci Rep
; 11(1): 19302, 2021 09 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34588467
4.
Pharmacokinetics and pharmacodynamics of tecarfarin, a novel vitamin K antagonist oral anticoagulant.
Thromb Haemost
; 117(4): 706-717, 2017 04 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28180234
5.
Pharmacokinetics of Tecarfarin and Warfarin in Patients with Severe Chronic Kidney Disease.
Thromb Haemost
; 117(11): 2026-2033, 2017 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-28933798
6.
A randomised, double blind comparison of tecarfarin, a novel vitamin K antagonist, with warfarin. The EmbraceAC Trial.
Thromb Haemost
; 116(2): 241-50, 2016 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27173100
7.
Treatment patterns and associated symptom improvement during six months of care for overactive bladder: a prospective, observational study.
Clin Ther
; 24(3): 397-408, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11952023
8.
Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: a one-year study.
Int Urol Nephrol
; 34(1): 43-9, 2002.
Artigo
em Inglês
| MEDLINE | ID: mdl-12549638
9.
A Phase 1 dose-ranging study examining the effects of a superabsorbent polymer (CLP) on fluid, sodium and potassium excretion in healthy subjects.
BMC Pharmacol Toxicol
; 15: 2, 2014 Jan 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-24460668
10.
A double-blind, randomized, parallel, placebo-controlled study examining the effect of cross-linked polyelectrolyte in heart failure patients with chronic kidney disease.
Eur J Heart Fail
; 14(8): 922-30, 2012 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-22613585
11.
Efficacy and safety of oxybutynin in children with detrusor hyperreflexia secondary to neurogenic bladder dysfunction.
J Urol
; 173(1): 221-5, 2005 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-15592080
12.
Effect of controlled-release delivery on the pharmacokinetics of oxybutynin at different dosages: severity-dependent treatment of the overactive bladder.
BJU Int
; 94(6): 821-7, 2004 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-15476516
13.
Regional heterogeneity of cerebral blood flow response to graded pressure-controlled hemorrhage.
J Trauma
; 56(3): 591-603, 2004 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-15128131
14.
Effect of pentosan polysulfate therapy on intravesical potassium sensitivity.
Urology
; 59(3): 329-33, 2002 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-11880064